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Lysophosphatidic Acid Up-Regulates
Hexokinase II and Glycolysis to
Promote Proliferation of Ovarian
Cancer Cells1
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Yongling Gong 3, Zhenyu Fang, Esraa M. Mohamed,
Erika Berrios, Huanjie Shao 4 and Xianjun Fang
Department of Biochemistry and Molecular Biology, Virginia
Commonwealth University School of Medicine, Richmond,
VA 23298

Abstract
Lysophosphatidic acid (LPA), a blood-borne lipid mediator, is present in elevated concentrations in ascites of ovarian
cancer patients and other malignant effusions. LPA is a potent mitogen in cancer cells. The mechanism linking LPA signal
to cancer cell proliferation is not well understood. Little is known about whether LPA affects glucose metabolism to
accommodate rapid proliferation of cancer cells. Here we describe that in ovarian cancer cells, LPA enhances glycolytic
rate and lactate efflux. A real time PCR-based miniarray showed that hexokinase II (HK2) was the most dramatically
induced glycolytic gene to promote glycolysis in LPA-treated cells. Analysis of the human HK2 gene promoter identified
the sterol regulatory element-binding protein as the primary mediator of LPA-induced HK2 transcription. The effects of
LPA on HK2 and glycolysis rely on LPA2, an LPA receptor subtype overexpressed in ovarian cancer and many other
malignancies. We further examined the general role of growth factor-induced glycolysis in cell proliferation. Like LPA,
epidermal growth factor (EGF) elicited robust glycolytic and proliferative responses in ovarian cancer cells. Insulin-like
growth factor 1 (IGF-1) and insulin, however, potently stimulated cell proliferation but only modestly induced glycolysis.
Consistent with their differential effects on glycolysis, LPA and EGF-dependent cell proliferation was highly sensitive to
glycolytic inhibition while the growth-promoting effect of IGF-1 or insulin was more resistant. These results indicate that
LPA- and EGF-induced cell proliferation selectively involves up-regulation of HK2 and glycolytic metabolism. The work is
the first to implicate LPA signaling in promotion of glucose metabolism in cancer cells.
Neoplasia (2015) 17, 723–734

Introduction
Lysophosphatidic acid (LPA), a lysophospholipid mediator, is present
in elevated concentrations in ascites of ovarian cancer patients and
other malignant effusions [1–3]. LPA regulates diverse biological
processes including proliferation, survival, migration and invasion of
tumor cells [4–6]. These effects of LPA are mediated via LPA binding
to its cognate G-protein coupled receptors (GPCRs) [4–6]. The
LPA1, LPA2 and LPA3 receptors are members of the endothelial gene
(Edg) subfamily of GPCRs. The purinergic family receptor LPA4 and
related LPA5, LPA6 and LPA7 receptors constitute the non-Edg
subgroup of LPA receptors, which are structurally distant from the
Edg LPA receptors [4–6]. The LPA receptors are expressed
differentially in adult tissues. Accumulating evidence suggests that
LPA receptors are functionally redundant or opposite. The cellular
responses to LPA are determined by the combination of various LPA
receptors and G proteins present in a cell [4,6–8].
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Among LPA receptors, LPA2 has been the most consistently
up-regulated in diverse human malignancies including cancers of
ovary [9], breast [10], stomach [11], colorectum [12] and thyroid
[13]. Overexpression of LPA2 has been linked to proliferation of
ovarian and colon cancer cells, and mesothelioma cells [14–16].
However, molecular mechanisms connecting LPA to proliferative and
other oncogenic processes remain poorly defined. We have recently
demonstrated that LPA stimulated de novo lipid synthesis in ovarian
cancer cells via LPA2-mediated up-regulation of lipogenic enzymes fatty
acid synthase and acetyl-CoA carboxylase [17]. The pro-lipogenic
action of LPA is essential for LPA-induced cell proliferation, likely
through contributing to membrane biogenesis. In addition to its role in
lipogenic metabolism, a number of previous studies suggest that LPA
may also regulate glucose uptake and metabolism. For examples, LPA
stimulated glucose transport in Xenopus oocytes [18], in ethanoltreated rat astrocytes [19], mouse L6 myotubes and 3 T3-L1 adipocytes
[20]. In the C13NJ microglia cell line, a proteome analysis indicated
LPA increased expression of several glycolytic enzymes such as
α-enolase and L-lactate dehydrogenase B [21]. In murine mesangial
cells, LPA was found to stimulate hexokinase II (HK2) expression and
glycolytic activity although the physiological relevance to LPA-coupled
biological functions was not explored [22]. It is generally believed that a
primary function of growth factors is to regulate glucose uptake and
catabolism, thus enabling anabolic pathways required for mitogenesis
[23]. This particularly applies to non-transformed cells where
steady-state aerobic glycolysis is generally low in the absence of growth
stimuli. Malignant cells are, however, metabolically transformed to
sustain a high basal glycolytic rate [24–26]. Hyperactive glycolysis not
only provides quick ATP but also serves as a primary route for carbon
influx, which is required for biosynthesis of complex macromolecules
and formation of organelles in actively proliferating cancer cells [24–
26]. Substantial evidence suggests that the glycolytic phenotype of
cancer cells is driven by overexpression or hyperactivity of key glycolytic
enzymes as a result of activation of oncogene and/or inactivation of
tumor suppressors [27–30]. Mutations of mitochondrial DNA that
impair functions of the respiratory complexes may also underlie high
glycolytic rate seen in cancers [31]. However, the contribution of
growth factors to cancer-associated glycolysis is unclear. It remains to be
determined whether cancer cell proliferation requires stimulation of
additional glycolysis over the high constitutive background.
No studies have thus far connected LPA to glucose metabolism in the
context of malignant cells. In the present study, we show that LPA
up-regulates glycolytic metabolism to promote proliferation of ovarian
cancer cells. The effect of LPA is mediated through LPA2-dependent
activation of the sterol regulatory element-binding protein 1 (SREBP-1)
and HK2 transcription. We further examined the general significance of
growth factor-induced glycolysis in cell proliferation and found that
LPA or epidermal growth factor (EGF), but not insulin-like growth
factor 1 (IGF-1) or insulin, relies on robust induction of glycolysis to
support proliferation of cancer cells. These findings revealed a
previously unrecognized role and mechanism for LPA in regulation of
glucose metabolism in cancer cells.
Materials and Methods

Reagents
LPA (1-oleoly, 18:1) was obtained from Avanti Polar Lipids, Inc.
(Alabaster, AL). Prior to use, LPA was dissolved in PBS containing
0.5% fatty acid-free bovine serum albumin (BSA) from Roche
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(Indianapolis, IN). D-[5- 3H(N)]-glucose was purchased from Perkin
Elmer (Boston, MA). EGF, 2-deoxy-D-glucose (2-DG), and AG
1478 were obtained from Sigma Aldrich (St. Louis, MO). IGF-1 and
insulin were from Invitrogen (Gaithersburg, MD). Plasmid DNAs
were purified using the endo-free purification kit from Qiagen
(Valencia, CA). Dharmafect 1 was obtained from Dharmacon, Inc.
(Lafayette, CO) and TransIT-TKO was obtained from Mirus Bio
(Madison, WI). Luciferase assay reagents were obtained from
Promega (Madison, WI). Anti-HK2 antibody was obtained from
Cell Signaling (Danvers, MA). The TaqMan Universal PCR Master
Mix and qPCR probes for HK2 and GAPDH were obtained from
Applied Biosystems (Carlsbad, CA).

Cell Culture
The sources of ovarian cancer cell lines were described previously
[16]. These cells were cultured in RPMI medium 1640 supplemented
with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin.
The cell lines were frozen at early passages and used for less than a
month in continuous culture.

Gene Knockdown
Lentiviruses carrying short hairpin RNA (shRNA) for LPA1–3
receptors were kind gifts from Dr. S. Huang (Georgia Regents
University) [32]. The siRNA oligos for LPA1, LPA2 LPA3, HK2 and
SREBP-1 were obtained from Applied Biosystems. Cells were plated
in 6-well plates. At around 50% confluence, cells were transfected
with target specific siRNA or non-targeting control siRNA (150 pM)
with Dharmafect 1 (4 μL, 12 to 16 hours) following the
manufacturer's protocol. Approximately 48 hours post transfection,
the cells were serum starved overnight before LPA treatment.

Western Blotting
Cells were lysed as previously described [33]. Total cellular proteins
were resolved by SDS-PAGE, transferred to immunoblot membrane
(polyvinylidene difluoride) (BIO-RAD, Hercules, CA), and immunoblotted with antibodies following the protocols of manufacturers.
Immunocomplexes were visualized with an enhanced chemiluminescence
detection kit from Amersham (Piscataway, NJ).

Quantitative PCR (qPCR)
Total cellular RNA was isolated from cultured cells using Trizol
(Invitrogen). Complementary DNA (cDNA) was synthesized using
the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). The relative levels of LPA1, LPA2, LPA3, HK2 and
GAPDH were determined by reverse transcription (RT) followed by
qPCR using gene specific probes, the TaqMan Universal PCR Master
Mix, and the Applied Biosystems 7900HT Real-Time PCR System.

Luciferase Assays
The human HK2 promoter sequence (− 1476 to + 73) [34] was
PCR amplified from human genomic DNA and cloned into the
pGL2-Basic-Luc at XhoI and HindIII sites to construct the luciferase
reporter pGL2-1476-HK2-Luc. The truncated forms (− 478 to + 73,
− 273 to + 73) were generated by PCR amplification of the
corresponding fragments from pGL2-1476-HK2-Luc and re-inserted
into the pGL2-Basic-Luc at the XhoI and HindIII sites. The promoter
sequences in these plasmids were verified by automatic sequencing.
Two potential consensus sites for SREBP (CCAGTCGCCCACACC
and CACGCTCCCCCCACCA) in pGL2-478-HK2-Luc were
converted into inactive sequences (CCAGGTGTCTTACACC and
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CACGCGTCTCTTACCA) by site-directed mutagenesis using
Lightning Site-Directed Mutagenesis Kit (Stratagene) following the
manufacturer's protocol. Primers used for these mutant constructs
were listed in Table 1. Caov-3 and OVCA-432 cells were transfected
with the luciferase vectors using TransIT-TKO according to the
manufacturer. About 48 hours after transfection, the cells were
starved overnight and treated with LPA or vehicle (BSA) for 12 to
16 hours. Cell extracts were prepared and assayed for luciferase
activity using a luciferase assay kit from Promega.

water bath, followed by centrifugation at 2000 g at 4°C for 5 minutes.
The cell extracts (50 μl) were added to 950 μl of reaction buffer (100 mM
Tris-HCl, pH 7.8, 5 mM ATP, 10 mM MgCl2, 10 mM glucose,
0.4 mM NADP, and 0.15 U/ml of G6PD (Sigma-Aldrich) and
incubated at 37°C. The HK enzymatic activity was monitored by
measuring glucose-6-phosphate dehydrogenase (G6PD)-dependent
conversion of NADP to NADPH spectrophotometrically at 340 nm.
The activity was presented as nanomoles of NADPH generated from one
milligram of protein per minute at 37°C.

PCR-Based Gene Expression Array

Quantification of Cellular ATP

The human glucose metabolism RT 2 profiler PCR array
(PAHS-006ZA) was obtained from Qiagen (Valencia, CA). Caov-3
cells were treated with LPA or vehicle for 12 hours before RNA isolation
using RNeasy mini kit (Qiagen). Complementary DNA (cDNA) was
synthesized using RT 2 First Strand Kit (Qiagen) and qPCR was carried
out using RT 2 SYBR®Green qPCR Mastermix according to the
manufacturer (Qiagen). The CT values were normalized to the levels of
GAPDH. Fold changes relative to vehicle-treated control cells were
calculated and presented in bar graphs.

Glycolysis
Glycolysis in cultured cells was measured as describes [28] with
some modifications. Briefly, cells were plated in 6-well or 12-well
plates, serum starved and treated with vehicle, LPA or other growth
factors for 12 to 16 hours. Radioactive glucose [5- 3H (N)] was added
to the medium at a concentration of 1 μCi/ml and incubated for 24
hours. Hydrochloric acid was then added to medium at a final
concentration of 0.2 N to terminate all biological reactions. The
acidified medium (0.6 ml) was collected into 15 ml high-clarity
polypropylene conical tubes (Falcon). A 0.5 ml micro centrifuge tube
containing 0.25 ml distilled water was uncapped and inserted into the
15 ml tube. Precautions were taken to prevent direct contact between
two solutions. The 15-ml tubes were tightly capped to allow diffusion
between two liquid phases for more than 48 hours. Radioactivities in
water and medium were determined by liquid scintillation counting.
The glycolytic rate was calculated with the formula 3.4a/(a + b) where
a is radioactivity present in water and b is activity present in the
medium [19].

Lactate Measurement
The lactate contents in culture supernatants were determined using
a lactate assay kit (Eton Bioscience, San Diego, CA) following the
protocol of the manufacture.

Hexokinase Activity Assay
Cells were lysed with a lysis buffer containing 15 mM Tris pH 7.8,
0.25 mM sucrose, 0.5 mM dithiothreitol (DTT), 1 mM aminohexanoic
acid, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 2 μg/ml
leupeptin. The lysates were then sonicated (5 times, 30 seconds each) in a
Table 1. Oligos Used in the Work
-1476
-478
-273
+73
SRE1
Mut
SRE2
Mut

5′-GCACTCGAGGGATTATGATTTTTGTTTATTTTTCCT-3′ (forward)
5′-GCACTCGAGCCGGCCGTGCTACAATAG-3′ (forward)
5′ -GCACTCGAGCTCATGCGCCTTTCCGTC-3′ (forward)
5′-GCAAAGCTTCGGATTTTCTTAGCTGGGTG-3′ (reverse)
5′-CAGAGGCCCGTTTTTCCAGGTGTCTTACACCCCGGGTCC GCGAT-3′ (forward)
5′-ATCGCGGACCCGGGGTGTAAGACACCTGGA AAA ACG GGC CTC TG-3′ (reverse)
5′-GGGTCCGCGATCACGCGTCTCTTACCCATAGCCGAGCCTG-3′ (forward)
5′-CAGGCTCGGCTATGGGTAAGAGACGCGTGATCGCGGACCCG-3′ (reverse)

After washing twice with PBS, cells in 6-well plates were lysed on
ice in H2O containing 0.75% NP-40 and vertexed at full speed for
10 seconds, and incubated on ice for 10 minutes. After centrifugation
(16,000g, 3 minutes), the supernatants were collected and diluted 100
times with H2O for ATP measurement with an ATP bioluminescence
assay kit (Sigma-Aldrich). ATP concentrations were calculated from the
standard curve and presented as nMol of ATP per 10 6 cells.

Statistics
All numerical data were presented as mean ± SD of triplicate assays,
representative of three independent experiments. The statistical
significances were analyzed using Student's t test unless otherwise stated,
where P b .05 was considered statistically significant. In all figures, the
statistical significances were indicated with * if P b .05 or ** if P b .01.
Results

LPA Activates Glycolysis in Ovarian Cancer Cells
LPA is an important mitogen in ovarian cancer and other neoplastic
cells. To understand the molecular mechanism of LPA-mediated cancer
cell proliferation, we examined whether LPA treatment stimulates glucose
metabolism using ovarian cancer cells as a model. During glycolysis, one
molecule of water is released when 2-phosphoglycerate is converted to
phosphoenolpyruvate. By labeling cells with 5- 3H glucose, we were able
to quantitate the glycolytic rate by measuring generation of 3H water
[28]. We treated a panel of ovarian cancer cell lines with LPA (10 μM)
and labeled the cells with 5- 3H glucose. LPA stimulated one- to four-fold
increases in glycolysis in ovarian cancer cell lines Caov-3 and OVCA-432
cells (Figure 1A). The LPA-induced increases in the glycolytic flux were
concurrent with significant rises in lactate present in culture supernatants
of LPA-treated cells (Figure 1A). Similar effects were observed in
LPA-treated OVCAR-3 and OVCAR-8 cells (data not shown).
LPA stimulated glycolysis in a dose-dependent manner similar to that
of the mitogenic response to LPA in these cells (Figure 1B). The LD50
values were approximately 0.3 to 0.6 μM in Caov-3 and 2.7 to 4.1 μM
in OVCA-432 cells. The activities reached plateau from 10 to 50 μM.
We subsequently used 10 μM LPA for the remainder of the study.

LPA Up-Regulates Expression of HK2 to Promote Glycolysis
LPA is known to up-regulate expression of a variety of pro-oncogenic
protein factors such as VEGF, COX-2, IL-6, IL-8, cyclin D1 and
kruppel-like factor 5 [35–41]. We determined whether LPA stimulated
glycolysis via regulation of any rate-limiting enzymes of the glycolytic
pathway. To this end, we treated Caov-3 cells with LPA for 12 hours
and isolated RNA to perform a PCR-based glucose metabolism array to
identify gene expression signatures involved in glycolysis. While LPA
treatment led to modest up- or down-regulation (less than three-fold) of
a number of glycolytic genes (Figure 2A), the most robust change was
close to 20-fold induction of HK2 by LPA. This pattern of changes in
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Figure 1. LPA activates glycolysis in ovarian cancer cells. (A) Ovarian
cancer cell lines in 6-well plates were treated with LPA (10 μM) or
vehicle for 12 to 16 hours before addition of 5-3H glucose (1 μCi/ml). The
cells were then incubated for 24 hours before measuring conversion of
5-3H glucose to 3H-H2O. The results were presented as % conversion
of glucose (upper). Lactate concentrations in culture supernatants were
quantified with a lactate assay kit (lower). (B) Caov-3 and OVCA-432 cells
in 12 well plates were treated with increasing concentrations of LPA
and glycolytic rate quantified as in (A). Cell numbers were determined
with a Coulter counter. For this and all following figures, data are mean
± SD of triplicates, representative of three independent experiments.
Statistical significances of data were determined by Student's t test and
indicted by * if P b 0.05 or by ** if P b 0.01.
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gene expression induced by LPA was reproducible in an independent
array experiment (Supplemental Figure S1). Quantitative PCR (qPCR)
analysis confirmed that LPA induced HK2 mRNA expression in
Caov-3 in a time-dependent manner with maximal level reached at
around 12 hours (Figure 2B). Similarly, LPA stimulated potent and
sustained induction of HK2 mRNA in OVCA-432 cells (Figure 2B).
Western blotting analysis confirmed that LPA induced expression
of HK2 protein in ovarian cancer cell lines (Figure 2C). The kinetics
of HK2 protein expression was essentially consistent with the time
course of LPA induction of HK2 mRNA. While HK2 mRNA peaked
around 12 hours, the protein levels reached a plateau between 12 and
16 hours. Compared to the multi-fold induction of HK2 mRNA, the
increases in the full-length HK2 protein did not seem to be
proportional, suggesting that post-transcriptional or post-translational
modifications of HK2 expression occurred. Indeed, on Western
blotting analysis of LPA-treated cells, prolonged exposure revealed a
novel band of approximately 70 kDa specifically present in
LPA-treated cells, likely representing a product cleaved from the
full-length HK2 following its induction.
The majority of HK2 protein in cells is attached to the mitochondria.
The mitochondria-associated HK2 is considered to be the active form of
the enzyme, contributing significantly to the cellular glycolytic
activity [42,43]. LPA stimulation increased both mitochondrial and
cytosolic fractions of HK2 (data not shown). In line with this,
LPA-treated cells showed significant increases in HK enzymatic activity
(Figure 2D). To gain molecular evidence for involvement of HK2 in
LPA-driven glycolysis, we used siRNA to knockdown HK2 expression.
As shown in Figure 2E, down-regulation of HK2 in these cells
attenuated LPA-driven glycolysis, indicating that HK2 mediates the
glycolysis-promoting effect of LPA.

LPA Stimulates HK2 Expression Through the SREBP-1
Transcription Factor
We next explored the mechanism underlying LPA up-regulation of
HK2. A fragment (− 1476 to + 73) of the human HK2 gene promoter
[34] was cloned from human genomic DNA and inserted into the
pGL2-Basic-Luc reporter. Serial deletion of 5′ sequences generated two
truncation mutants containing − 478 to + 73, and − 273 to + 73
fragments of the promoter. These constructs were transfected into
Caov-3 and OVCA-432 cells, and LPA-induced luciferase activity was
determined by luciferase assays. As illustrated in Figure 3, LPA
treatment stimulated a multi-fold increases in luciferase activity in cells
transfected with pGL2-1476 to + 73-Luc. Comparable stimulation of
luciferase activity by LPA was observed in cells transfected with
pGL2-478 to + 73-Luc. However, further deletion to − 273 to + 73
resulted in a drastic decrease in luciferase activity induced by LPA
(Figure 3), suggesting that major responsive element(s) required for
LPA stimulation resided within the sequence between − 478 and − 273.
The Insilico analysis revealed several potential cis regulatory elements
within this region, including sites for cAMP-responsive element
binding protein, nuclear factor 1, specificity protein 1 (Sp1) and
SREBP. We have previously shown that LPA activates Sp1 and SREBP
in ovarian cancer cells [17,36]. However, Sp1 is a transcription factor
activated rapidly following LPA treatment [36], which does not echo
the delayed HK2 induction in LPA-treated cells. HK2 has been
previously shown to be transcriptionally induced by SREBP-1 in
human myocytes [44] and in rat adipose tissue and skeleton muscles
[45]. The existence of two closely positioned sterol response elements
(SREs) within the responsive region and strong activation of SREBP by
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Figure 2. LPA stimulates expression of HK2. (A) Caov-3 cells were treated with LPA (10 μM) or vehicle (BSA) for 12 hours. The human
glucose metabolism RT 2 profiler PCR array was performed on cDNAs prepared from total cellular RNA as described in Experimental
Procedures. Expression levels of glycolytic genes were normalized on GAPDH and then compared between LPA-treated and control cells
and presented as fold changes over vehicle controls (defined as arbitrary 1). (B, C) Caov-3 and OVCA-432 cells were treated with LPA (10
μM) for the indicated periods of time (hours). Induction of HK2 mRNA (B) and protein (C) was analyzed by RT-qPCR and immunoblotting,
respectively. HK2 protein levels were quantified by densitometry and presented as fold changes relative to control cells. (D) Hexokinase
activity was determined in Caov-3 and OVCA-432 cells treated for 16 hours with LPA or vehicle and presented as nanomoles/mg protein/
min at 37 °C. (E) HK-2 expression was down-regulated by HK2 specific siRNA in Caov-3 and OVCA-432 cells. LPA-induced glycolysis in
HK-2 knockdown and control siRNA-treated cells were determined as described in Figure 1.
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knockdown expression of LPA1, LPA2, or LPA3 in Caov-3 cells.
Knockdown of LPA2 but not other Edg LPA receptors, led to
suppression of LPA-induced HK2 expression (Figure 4). A similar
result was observed in OVCA-432 cells where LPA receptors were
stably knocked down using lentivirus-mediated shRNA (Figure 4).
Consistent with the requirement of HK2 for LPA-induced glycolysis,
knockdown of LPA2 in both cell lines inhibited LPA-induced
glycolysis (Figure 4). Therefore LPA2 is the major LPA receptor
subtype accounting for LPA up-regulation of HK2 and glycolysis in
ovarian cancer cells. The conclusion is also consistent with the
essential role of LPA2 in LPA-dependent activation of SREBP as we
demonstrated recently [17]. In addition to ovarian cancer cells, we
also examined the effects of LPA in breast and colon cancer cell
lines that have been reported to overexpress LPA2 [10,15,48]. As
shown in Figure 4B, LPA stimulated HK2 expression, glycolysis
and proliferation of the MDA-231 breast cancer and HCT116 colon
cancer cell lines.

HK2
1.0 6.2 1.0 0.7

1.0

1.9 1.0 1.2

Tubulin
Caov-3

OVCA-432

Figure 3. LPA stimulates HK-2 expression through transcriptional
activation mediated by SREBP. (A) Caov-3 and OVCA-432 cells were
transfected with the indicated luciferase constructs. After 48 hours,
transfected cells were starved for 16 to 24 hours and then treated
for 16 hours with LPA (10 μM) or vehicle before measurement of
luciferase activity with a luminometer. LPA-induced luciferase
activities were presented as fold increases over vehicle-treated control
cells. (B) LPA-induced HK2 expression in SREBP-1 siRNA knockdown
cells and control cells (Ctrl-si) was analyzed by immunoblotting and
densitometry. The cells were treated for 16 hours with 10 μM LPA
or vehicle.

LPA in ovarian cancer cell lines [17] prompted us to examine the
potential role of SREBP in transcriptional activation of HK2. As shown
in Figure 3A, mutation of either SRE sites (SRE1 or SRE2) significantly
reduced LPA-driven luciferase activity. Simultaneous mutation of both
SRE sites, however, did not further eliminate LPA-induced activity.
The remaining response of the double mutant was similar to that of
individual mutation. The results indicated that the two adjacent SREs
act in concert to drive HK2 transcription. Interestingly, the SREBP-1
regulation of the fatty acid synthase promoter has been also reported to
rely on two tandem SRE sites for full activation [46]. In further support
of the role of SREBP, siRNA knockdown of SREBP-1abrogated
LPA-dependent up-regulation of HK2 in Caov-3 cells (Figure 3B).
SREBP siRNA also consistently reduced LPA-induced HK-2 protein
expression in OVCA-432 cells. The minor remaining activity in
OVCA-432 cells (Figure 3B) could be due to incomplete knockdown or
the presence of SREBP1-independent input.

LPA2 is the Major LPA Receptor That Mediates HK2
Expression and Glycolysis
Caov-3, OVCA-432 and other ovarian cancer cell lines express the
Edg LPA receptors LPA1, LPA2, and LPA3 while the non-Edg
receptors are either absent or are expressed inconsistently among
ovarian cancer cell lines [38,47]. To identify the LPA receptor
subtype responsible for the pro-glycolytic action of LPA, we focused
on the Edg LPA receptors. LPA receptor siRNA was used to

Growth Factors Differ in Their Ability to Activate HK2
Expression and Glycolysis
Although active glycolysis is a general phenomenon of rapidly
growing cancer cells, few studies have addressed potential regulatory
role of growth factors present in tumor microenvironments. To
understand the general role of glycolytic metabolism in cancer cell
proliferation, we compared LPA with a number of growth factors
involved in ovarian cancer pathogenicity including EGF, IGF-1, and
insulin. Interestingly, when their proliferative responses were adjusted
to be at similar levels by using appropriate concentrations of growth
factors, their glycolytic activities varied dramatically (Figure 5A). LPA
and EGF strongly activated glycolysis while IGF-1 and insulin
showed only modest stimulatory effects on glycolysis, not proportional to their mitogenic activities. Likewise, IGF-1 and insulin only
slightly increased HK2 expression in contrast to the strong induction
of HK2 by LPA or EGF in these cells (Figure 5B). In addition, all
these growth factors increased cellular ATP levels in Caov-3 and
OVCA-432 cells (Figure 5A).
LPA has been shown to transactivate EGFR, which is involved in
diverse biological responses to LPA [38]. The similarity between LPA
and EGF in up-regulation of HK2 and glycolysis suggests that LPA
may exert its effects via EGFR transactivation. We examined the
possibility by treatment of Caov-3 and OVCA-432 cells with LPA in
the presence of the EGFR specific inhibitor AG 1478. As
demonstrated in Figure 5C, inhibition of EGFR prevented LPA
from inducing HK2 expression and glycolysis in these cells.

LPA and EGF Stimulates Glycolysis to Promote
Cell Proliferation
The differential effects of LPA, EGF, IGF-1 and insulin suggest that
robust induction of glycolysis by growth factors may not be necessarily
required to support active cell proliferation. A modest increase such as
that seen in IGF-1 or insulin-stimulated cells may be sufficient to supply
cells with quick energy and biosynthetic intermediates. The excess
glycolysis seen in the context of LPA or EGF stimulation may be
redundant and indispensable for cell proliferation. Hyperactive
glycolysis and/or lactate production in vivo have been linked to other
non-autonomous cellular functions in cancer such as acidification of
extracellular environment and evasion of immune surveillance [49,50].
To address whether up-regulation of glycolysis is indeed required for
LPA-induced cell proliferation, we used 2-DG, a well-defined glycolytic
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Figure 4. LPA2 is the major LPA receptor subtype responsible for HK2 induction and glycolysis. Each of LPA1-3 receptors was knocked down
by siRNA in Caov-3 cells or by lentivirus-transduced shRNA in OVCA-432 cells. (A) The cells were serum starved and treated with LPA (10 μM)
or vehicle for 16 hours before immunoblotting analysis of HK2 protein. (B) Glycolysis of these cells was determined as in Figure 1 and the
results were presented as fold increases relative to vehicle-treated control cells (defined as one fold). (C) LPA-induced increases in HK2
expression and glycolysis were reproduced in LPA2-expressing MDA-231 breast cancer and HCT116 colon cancer cell lines.

inhibitor that targets primarily HK2 to prevent glucose from entering
the glycolytic pathway [51,52]. To this end, Caov-3 and OVCA-432
cells were stimulated with LPA, EGF, IGF-1 or insulin in the presence
or absence of 2-DG. We chose nontoxic concentrations of 2-DG so that
LPA-driven glycolysis was significantly reduced but remained to be
higher than the levels in IGF- or insulin-stimulated cells. As shown in

Figure 6, this partial inhibition of glycolysis was sufficient to suppress
LPA-induced proliferation in Caov-3 and OVCA-432 cells.
EGF-induced growth of these cells was also sensitive to the partial
inhibition of glycolysis. However, in Caov-3 cells, 2-DG only slightly
inhibited IGF-1- or insulin-induced glycolysis. Consistent with this,
2-DG did not significantly affect mitogenic activity of insulin or IGF-1.
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Discussion
Previous studies in Xenopus oocytes, primary mammalian cells such
as rat astrocytes and murine mesangial cells, and murine cell lines
hinted at the possibility that LPA up-regulates glucose metabolism in
these non-transformed cells although the related physical significance
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In OVCA-432 cells, 2-DG had little, if any, effects on either glycolytic
or proliferative effects of IGF-1 or insulin (Figure 6). The results
indicate that enhancement of glycolysis is specifically required as an
integral component of the complex proliferative response to LPA
or EGF.
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Figure 5. LPA, EGF, insulin and IGF-1 display differential effects on glycolysis and HK2 expression. (A) Caov-3 and OVCA-432 cells in 6-well
plates were serum starved and treated with LPA (10 μM), IGF-1 (20 ng/ml in Caov-3, 25 ng/ml in OVCA-432), insulin (10 μg/ml in Caov-3,
0.125 μg/ml in OVCA-432), or EGF (40 ng/ml in Caov-3, 2 ng/ml in OVCA-432). Cell numbers, glycolysis, and lactate levels were determined
as in Figure 1. ATP contents in the cells treated for 20 hours with each of these growth factors were measured with an ATP
bioluminescence assay kit and the data presented as nMol ATP per 10 6 cells. (B) Immunoblotting analysis of HK2 induction was
performed in Caov-3 and OVCA-432 cells stimulated for 16 hours with LPA, EGF, IGF-1 or insulin as described in (A). (C) The effects of LPA
on glycolysis and HK2 expression were examined as in (A) and (B) in the absence or presence of the EGFR inhibitor AG 1478 (0.75 μM). AG
1478 was added to culture 0.5 hour before LPA.
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However, LPA strongly stimulated glycolytic flux and lactate
production in cells of Caov-3, OVCA-432 and other ovarian cancer
lines. A glucose metabolism PCR array led to the identification of
HK2, the enzyme catalyzing the irreversible first rate-limiting step of
glycolysis, as most markedly induced by LPA. We further
demonstrated that LPA stimulated HK2 expression through LPA2dependent activation of SREBP. To understand biological significance of LPA-regulated glycolysis, we compared LPA with EGF,
IGF-1 and insulin. Interestingly, their glycolysis-promoting activities
varied considerably. LPA and EGF strongly activated glycolysis while
IGF-1 and insulin exhibited only modest effects, not proportional

**

is unknown [18–22]. Such a role of LPA in glucose metabolism,
however, has not been extended to malignant cells which generally
maintain high basal levels of glycolysis [24–26]. We have recently
reported that LPA enhances de novo lipogenesis in ovarian cancer cells
[17]. Since the increase in lipid biosynthesis requires not only
activation of lipogenic enzymes but also the availability of the lipid
synthesis precursor acetyl-CoA, an important intermediate of glucose
metabolism. We thus speculated that LPA might play a more general
role in cancer cell metabolism. We initially monitored the effect of
LPA on expression of glucose transporters (GLUT1, GLUT4) but did
observe any significant changes in response to LPA. Consistently,
LPA did not increase glucose transport into ovarian cancer cells as
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Figure 6. Up-regulation of glycolysis is required for LPA and EGF-induced cell proliferation. Caov-3 and OVCA-432 cells were treated in the
same conditions as in Figure 5A in the presence of 2-DG (1.25 mM in Caov-3 and 3 mM in OVCA-432) or vehicle. 2-DG was added 12 hours
after the growth factors. Cell numbers (upper) and glycolysis (lower) stimulated by these growth factors were quantified as in Figure 1.
The data were presented as fold increases over the corresponding controls that are defined as one fold.
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to their potent mitogenic activities. In line with the differential
effects, LPA- or EGF-driven cell proliferation depends on the strong
up-regulation of glycolysis.
Malignantly transformed cells exhibit an altered metabolic profile
exemplified by a heightened glycolytic rate in normoxic conditions or
the Warburg effect [24–26]. Tumors at advanced stages often
experience hypoxia, leading to stabilization of HIF-1α protein, an
important regulator of many glycolytic enzymes [53]. However,
hypoxia is not the causal factor of the glycolytic phenotype that occurs
in both hypoxic and oxygenated regions of a tumor. Tumor cells
in vitro also glycolyse when cultured in normoxic conditions. Ras,
Akt, and c-Myc have been reported to activate expression of various
glycolytic enzymes [27–29]. In contrast, loss of the p53 tumor
suppressor inhibits the mitochondrial respiratory chain by suppression of SCO2 (the synthesis of cytochrome c oxidase protein) and
promotes glycolysis via TIGAR, a p53-inducible regulator of
glycolysis and apoptosis [30]. However, these defects present only
in some tumors do not explain the generally altered pattern of glucose
metabolism in a wide spectrum of cancers. Other unrecognized
mechanisms are likely important in the development and maintenance of the glycolytic phenotype of cancer cells. The results of the
present study suggest that growth factors such as LPA and EGF could
contribute significantly to the high glycolytic levels seen in cancer
cells. Moreover, up-regulation of glycolysis is essential for LPA- or
EGF-dependent cell proliferation. The requirement suggests the
importance of glycolysis to meet the bioenergetic and biosynthetic
demands of proliferatively active cancer cells.
In contrast to LPA and EGF, IGF-1 and insulin are relatively weaker
stimuli of glycolysis in ovarian cancer cells although they exhibited as
strong mitogenic activities. IGF-1 or insulin-driven growth of ovarian
cancer cells was not much affected by 2-DG. This is not surprising as the
glycolytic inhibitor did not decrease glycolytic levels in IGF-1- or
insulin-treated cells as dramatically as in LPA- or EGF-stimulated cells.
The result also suggests that a modest increase in glycolysis was adequate
to meet requirements of bioenergy and biomasses for proliferation of
IGF-1 or insulin-stimulated cells. Alternatively, as physiological
endocrine factors, IGF-1 and insulin could modulate other metabolic
processes such as lipid oxidation and glutamate metabolism to
compensate for relatively restrained glycolysis [54–56].
A mechanistic finding of the current study is that LPA induces
glycolysis through LPA2 activation of SREBP to enhance HK2
expression. We have previously shown that LPA2-dependent
activation of SREBP is also involved in LPA induction of the
lipogenic enzyme FAS to promote de novo lipid synthesis [17]. The
results of the current study suggest that SREBP acts as a transcription
factor that up-regulates expression of HK2 as well. Therefore SREBP
lies at a convergence point to coordinately regulate both lipid
anabolism and glucose catabolism in LPA-stimulated cells.
Compared to other LPA receptors, LPA2 is most commonly
overexpressed in various cancers. A number of recent studies have
provided strong evidence that LPA2 is causally linked to tumorigenesis
in animals. Liu et al reported that transgenic expression of LPA receptors
driven by the MMTV promoter leads to development of mammary
tumors including estrogen receptor-positive and -negative breast
carcinomas [57]. LPA2 transgenic mice showed a more aggressive
tumorigenic phenotype compared to the LPA1 or LPA3 transgenic
animals [57]. The most direct evidence to implicate LPA2 in cancer
stems from the recent studies by Yun's group using the LPA2 null mice
[58,59]. Compared to wild type mice, LPA2-deficient mice were more
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resistant to intestinal tumorigenesis induced by colitis or by ApcMin
mutation [58,59]. The oncogenic mechanism of LPA2 remains elusive.
Most studies have focused on the ability of LPA2 to stimulate expression
of oncogenic mediators [35–41]. The link from LPA to activation of
HK2 expression and glycolytic metabolism as revealed by the present
study reflects another oncogenic process mediated primarily by LPA2.
Given the prominent pro-oncogenic function of LPA2 and its
non-essential physiological role in mice [60], LPA2 could be an ideal
target for therapeutic intervention of cancer.
Conclusions
In sum, LPA stimulates glycolysis through induction of HK2. The
effect of LPA is mediated by the LPA2 receptor-dependent activation
of the SREBP transcription factor. Further functional analysis
indicates that growth factors involved in ovarian oncogenesis exhibit
differential effects on glycolysis. Like LPA, EGF strongly activates
glycolysis while IGF-1 and insulin induce glycolysis at a modest level,
not proportional to their strong mitogenic activity. Consistently, LPA
or EGF relies on robustly enhanced glycolysis to support cell
proliferation while the mitogenic activity of IGF-1 or insulin is largely
resistant to glycolytic inhibition. The work represents the first to link
LPA signaling to glucose metabolism and the glycolytic phenotype of
cancer cells.
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